VKTX positioning suggests potential for trading spikes around pipeline updates or buyout leaks, with momentum building into phase three results and FDA approval catalysts.

Dual GIPR/GLP-1 agonist VK2735 is progressing through Phase 3 development in both subcutaneous (VANQUISH-1/2) and oral formulations, with patient enrollment completed in VANQUISH-2 and a plan to initiate oral Phase 3 in Q3 2026. VK2809 achieved primary and secondary endpoints in a Phase 2b NASH study. Viking projects $118.5 M in revenue and $12.9 M in earnings by 2029.

Smaller biotech firms are challenging established players by advancing dual GIPR/GLP-1 receptor agonists in both oral and subcutaneous forms for obesity treatment.

Investors are confident Viking’s next-gen dual GLP-1/GIP candidates will deliver best-in-class oral and injectable obesity treatments with blockbuster potential, viewing the shares as undervalued and poised for significant upside, while still bracing for Phase 3 readouts, safety and tolerability questions, ongoing losses, and competitive or regulatory setbacks.

VKTX suffered a 42% intraday drop on August 19, 2025 following mid-stage trial results, but renewed buying flows have emerged as ACT Capital built a 206,100-share position ahead of upcoming catalysts.

Completed full enrollment in Phase 3 VANQUISH-2 for subcutaneous VK2735 and on track to initiate oral Phase 3 in Q3 2026, backed by a $706 million cash runway, dual oral/SC VK2735 obesity programs, successful Phase 2b NASH candidate VK2809, and initial revenue projected at $118.5 million by 2029.

VK-2735's oral and injectable weight-loss regimens have advanced into Phase 3 following regulator meetings, with bioequivalence data supporting an autoinjector variant; approval will hinge on hepatic safety guardrails that restrict use to patients without fatty liver or hepatitis, and the program’s resource demands necessitate external partnerships amid takeover speculation.

Investor optimism around Viking’s next-generation obesity candidate is high, driven by expectations that the maintenance trial and oral formulation will confirm its potency and convenience, fueling takeover chatter and lofty price targets despite some caution over near-term losses and cash burn.

VKTX saw a significant midday rally up 9.6%, while Viking Therapeutics and Amgen faced afternoon selling pressure, with declines over 3% and 1%, respectively.

Oral VK2735 is set to enter Phase 3 VANQUISH trials in Q3 2026 following successful Phase 1/2 results and ahead-of-schedule enrollment—over 4,500 patients are now enrolled across VANQUISH-1 and ‑2. The company maintains over $700 million in cash to fund its obesity programs, while R&D outlays drove a Q4 2025 net loss of $157.7 million and a drop in current assets to $715.6 million.

Obesity drug competition in the cash-pay consumer market is intensifying as U.S. prices for GLP-1 treatments from Novo Nordisk and Eli Lilly fall sharply, even as Viking’s dual GLP-1/GIP agonist VK2735 advances through Phase 3 trials with over 4,500 patients enrolled.

Investors are bullish on VK2735’s phase 3 momentum and potential for outsized returns, framing Viking as significantly undervalued, while remaining wary of steep losses and regulatory or clinical setbacks.

Share price has fallen 16% over the past month and 22% over the past year, erasing multi-year momentum, while the CFO sold $1.9 million of stock in open-market transactions.

VK2735 delivered 14.7% weight loss in Phase 2 with no plateau, triggering two large Phase 3 VANQUISH trials that have rapidly enrolled thousands of patients and are nearing completion, supported by a cash balance sufficient to fund through Phase 3 and future pipeline expansion.

Viking Therapeutics lacks any marketed or approved drugs, so no revenues are expected next quarter and it faces intense competition from established pharma; its pipeline includes obesity therapies (VK2735 oral and subcutaneous dual GIP/GLP-1 RA and a dual amylin/calcitonin receptor agonist entering IND), VK2809 for lipid and metabolic disorders, VK0214 for X-ALD, and a new chief commercial officer has been appointed.

Breakthrough Phase 2 weight-loss data and rapid Phase 3 enrollment have driven bullish narratives and a strong-buy consensus with triple-digit upside price targets, but persistent pre-revenue losses, steep EPS downgrades, a Zacks sell ranking and premium valuation metrics inject skepticism and highlight execution and regulatory risks.